This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
by Zacks Equity Research
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of +73.65% and +22.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
by Zacks Equity Research
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform in the third quarter.
Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
IQVIA Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
IQV readies its Q3 report, with revenues and EPS expected to rise on biopharma strength and cost control despite muted beat odds.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
by Zacks Equity Research
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
by Zacks Equity Research
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
by Zacks Equity Research
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
Why Alnylam (ALNY) Might be Well Poised for a Surge
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
by Zacks Equity Research
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice
by Zacks Equity Research
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy
by Zacks Equity Research
Rocket Pharmaceuticals surges as the FDA accepts its resubmitted BLA for Kresladi, a gene therapy targeting the rare LAD-I disorder.
Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock?
by Zacks Equity Research
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
by Zacks Equity Research
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
by Zacks Equity Research
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.